Galapagos NV ADR is a biotechnology business based in the US. Galapagos NV ADR shares (GLPG) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $29.27 – a decrease of 1.58% over the previous week. Galapagos NV ADR employs 683 staff and has a trailing 12-month revenue of around $261.4 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $29.27 |
|---|---|
| 52-week range | $24.16 - $42.46 |
| 50-day moving average | $27.75 |
| 200-day moving average | $31.07 |
| Wall St. target price | $30.71 |
| PE ratio | 56.1132 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $0.53 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $29.27 from 2024-10-14
| 1 week (2024-10-09) | -0.24% |
|---|---|
| 1 month (2024-09-16) | -4.56% |
| 3 months (2024-07-16) | 11.00% |
| 6 months (2024-04-16) | -0.75% |
| 1 year (2023-10-16) | -15.70% |
|---|---|
| 2 years (2022-10-14) | -32.67% |
| 3 years (2021-10-15) | 53.52 |
| 5 years (2019-10-16) | 161.68 |
Valuing Galapagos NV ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Galapagos NV ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Galapagos NV ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 56x. In other words, Galapagos NV ADR shares trade at around 56x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
| Revenue TTM | $261.4 million |
|---|---|
| Gross profit TTM | $4.8 million |
| Return on assets TTM | -1.76% |
| Return on equity TTM | 1.15% |
| Profit margin | 108.11% |
| Book value | $44.16 |
| Market Capitalization | $2 billion |
TTM: trailing 12 months
We're not expecting Galapagos NV ADR to pay a dividend over the next 12 months.
Over the last 12 months, Galapagos NV ADR's shares have ranged in value from as little as $24.16 up to $42.455. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galapagos NV ADR's is 0.094. This would suggest that Galapagos NV ADR's shares are less volatile than average (for this exchange).
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. ; and AbbVie S. à r. l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Explore the best bonuses for opening a new brokerage account.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out the best-performing ETFs so far in 2024.
Read our beginner’s guide to trading options in the US.